Ultragenyx Pharmaceutical, Inc. RARE

Fayuvi Adds a New Revenue Stream, but Ultragenyx’s 2027 Goal Faces Pressure

The FDA approval opens a route to sales, while a failed Angelman trial and ongoing losses complicate Ultragenyx’s path to profitability.